Lead designated Market Access Strategy Teams for a portfolio of oncology assets across solid tumors and hematological malignancies, with a focus on prostate cancer and multiple myeloma.
Base: 162,750.00- 212,750.00; Bonus/Equity: discretionary performance bonus; Benefits: Not specified
Must-have
Nice-to-have
Not specified